Study: Bypass surgery outperforms Boston Scientific's Taxus

A study of 3,000 patients in 85 U.S. and European hospitals found that 17.8% of those who received Boston Scientific's Taxus drug-coated stent died, experienced a stroke or heart attack, or underwent repeat procedures after a year, compared with 12.1% of those who got bypass surgery. An analysis of the company-sponsored study found no marked difference regarding safety between the two procedures within the first year -- a result that gives patients more options, a cardiologist said.

View Full Article in:

Wall Street Journal (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA